- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Burris on the Impact of the ASCO Annual Meeting
Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.
Howard Burris, III, MD, Giant of Cancer Care in Drug Development, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute, discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.
One of the biggest benefits of ASCO’s annual meeting is the world’s thought-leaders coming together to present, discuss, and debate the latest results and research in cancer, says Burris. However, the ‘hallway conversations’ that happened amongst attendees and presenters off of the podium are just as meaningful. A lot of ideas and collaborations throughout the industry occur this way, he says.
At this year’s conference, Burris is most looking forward to research regarding the harnessing of the immune system to fight cancer. This is an area that has been discussed abstractly for many years, but only recently became a topic in which concrete data was presented at ASCO, says Burris.
<<<